Observed Signal · Nov 16, 2026 · funding · Source: SEC API · Impact: 2/5

Novo Nordisk Repurchases DKK 310 Million of B Shares Under Buyback Programme

Executive Signal Summary

On November 16, 2026, Novo Nordisk disclosed weekly transactions under its ongoing share repurchase programme executed in accordance with EU Safe Harbour Rules. Between November 9 and November 13, 2026, the company repurchased 1,130,000 B shares for a total consideration of approximately DKK 310.06 million, bringing accumulated buybacks under the May 2026 tranche to 28,975,000 B shares valued at DKK 8.32 billion. Overall, since February 4, 2026, Novo Nordisk has repurchased 43,734,179 B shares for DKK 12.12 billion under its 12-month DKK 15 billion buyback plan. Following these transactions and net incentive transfers, Novo Nordisk holds 57,645,131 treasury B shares, representing roughly 1.3% of total share capital.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Routine weekly reporting update regarding capital allocation and ongoing execution of an authorized DKK 15 billion share repurchase programme.

MARKET SIGNALS

Track Novo Nordisk Signals & Strategic Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • Repurchased 1,130,000 B shares between 9 November and 13 November 2026 for DKK 310,059,558.
  • Accumulated buybacks under the 6 May 2026 sub-programme reached 28,975,000 B shares valued at DKK 8,318,073,280.
  • Total repurchases since 4 February 2026 reached DKK 12,118,073,269 across 43,734,179 B shares against the DKK 15 billion authorization.
  • Treasury share holding stands at 57,645,131 B shares, accounting for 1.3% of total share capital.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: SEC API•Published: Nov 16, 2026

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

financialsNov 9, 2026

6-K Financial Filing Analysis for Novo Nordisk (2026-11-09)

On November 9, 2026, Novo Nordisk published a Form 6-K providing an operational update on its ongoing share repurchase programme conducted under EU Market Abuse Regulation Safe Harbour rules. The update covers market repurchases executed between November 3 and November 6, 2026, during which the company acquired 890,000 B shares for a total consideration of approximately DKK 243.65 million. This tranche forms part of the broader DKK 15 billion annual buyback programme launched on February 4, 2026, and the specific DKK 11.2 billion sub-programme running through February 1, 2027. Following these transactions, Novo Nordisk holds 56,644,876 B shares in treasury, representing 1.3% of its total share capital of 4,465,000,000 shares. In total, since February 4, 2026, the company has repurchased 42,604,179 B shares for an aggregate transaction value of DKK 11.81 billion at an average price of DKK 277.16 per share, underscoring ongoing disciplined capital returns to shareholders backed by strong cash flow from its core diabetes and obesity franchises.

Read assessment
financialsOct 19, 2026

6-K Financial Filing Analysis for Novo Nordisk (2026-10-19)

Novo Nordisk filed a Form 6-K on October 19, 2026, detailing weekly transaction activity under its ongoing share repurchase programme conducted in accordance with EU Market Abuse Regulation safe harbour rules. Between October 12 and October 16, 2026, the company repurchased 1,225,000 Class B shares for a total consideration of DKK 316,147,881, bringing the total accumulated under the sub-programme initiated on May 6, 2026, to 24,315,000 B shares valued at DKK 7,075,024,314. Overall, under the broader 12-month DKK 15 billion buyback programme initiated on February 4, 2026, Novo Nordisk has acquired 39,074,179 B shares for a total of DKK 10,875,024,304 at an average price of DKK 278.32 per share. Following these transactions, Novo Nordisk holds 53,114,876 treasury B shares, representing approximately 1.2% of the company's total share capital.

Read assessment
financialsNov 3, 2026

6-K Financial Filing Analysis for Novo Nordisk (2026-11-03)

Novo Nordisk published a regular weekly transaction update under its ongoing share repurchase programme, executed pursuant to EU Market Abuse Regulation Safe Harbour rules. During the trading week ending 2 November 2026, the company repurchased 1,440,000 B shares across six trading sessions for a total transaction value of DKK 377,016,699, bringing cumulative buybacks under the sub-programme initiated on 6 May 2026 to 26,955,000 B shares (DKK 7.76 billion). Following these transactions, Novo Nordisk holds 55,754,876 B shares as treasury stock, representing approximately 1.2% of its total share capital. Across the broader 12-month DKK 15 billion buyback framework launched on 4 February 2026, the company has repurchased an aggregate of 41,714,179 B shares for DKK 11.56 billion.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for Novo Nordisk & competitors in your briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context